Table 3.
Scale | Direction | Anchor | AUC | Optimal threshold | Sensitivity | Specificity |
---|---|---|---|---|---|---|
Disease symptoms | Deterioration | FACT‐GOG‐Ntx MT | 0.631 | 5.6 | 0.429 | 0.813 |
Disease symptoms | Deterioration | FACT‐GOG‐Ntx EOT | 0.662 | 5.6 | 0.500 | 0.751 |
Disease symptoms | Improvement | FACT‐GOG‐Ntx MT | 0.702 | −11.1 | 0.613 | 0.699 |
Disease symptoms | Improvement | FACT‐GOG‐Ntx EOT | 0.644 | −11.1 | 0.506 | 0.699 |
Side effects | Deterioration | FACT‐GOG‐Ntx MT | 0.722 | 6.7 | 0.652 | 0.709 |
Side effects | Deterioration | FACT‐GOG‐Ntx EOT | 0.764 | 10.0 | 0.632 | 0.784 |
Side effects | Deterioration | Matched AEs | 0.711 | 6.7 | 0.750 | 0.571 |
Side effects | Improvement | FACT‐GOG‐Ntx MT | 0.735 | −3.3 | 0.707 | 0.670 |
Side effects | Improvement | FACT‐GOG‐Ntx EOT | 0.743 | −6.7 | 0.624 | 0.784 |
Body image | Deterioration | FACT‐GOG‐Ntx EOT | 0.601 | −33.3 | 0.380 | 0.787 |
Body image | Improvement | FACT‐GOG‐Ntx EOT | 0.661 | 33.3 | 0.435 | 0.833 |
Future perspective | Deterioration | FACT‐GOG‐Ntx EOT | 0.595 | −11.1 | 0.268 | 0.871 |
Future perspective | Improvement | FACT‐GOG‐Ntx EOT | 0.592 | 11.1 | 0.400 | 0.740 |